For research use only. Not for therapeutic Use.
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody targets the p19 subunit of interleukin 23. Mirikizumab can be used for the research of ulcerative colitis[1].
| Catalog Number | I042088 |
| CAS Number | 1884201-71-1 |
| Purity | ≥95% |
| Reference | [1]. Jefremow A, et al. Some are More Equal: Targeting IL 12 and 23 in IBD – A Clinical Perspective. Immunotargets Ther. 2020 Nov 26;9:289-297. |
